Cargando…

Effects of Dairy Products Consumption on Health: Benefits and Beliefs—A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes with a dairy-free diet. Despite the established benefits for bone health, some people avoid dairy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rozenberg, Serge, Body, Jean-Jacques, Bruyère, Olivier, Bergmann, Pierre, Brandi, Maria Luisa, Cooper, Cyrus, Devogelaer, Jean-Pierre, Gielen, Evelien, Goemaere, Stefan, Kaufman, Jean-Marc, Rizzoli, René, Reginster, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703621/ https://www.ncbi.nlm.nih.gov/pubmed/26445771 http://dx.doi.org/10.1007/s00223-015-0062-x

Ejemplares similares

Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club
por: Body, J.-J., et al.
Publicado: (2011)

Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club
por: Laurent, Michaël R., et al.
Publicado: (2022)

Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club
por: Gielen, E., et al.
Publicado: (2017)

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
por: Body, J.-J., et al.
Publicado: (2010)

Health Technology Assessment in Osteoporosis
por: Hiligsmann, Mickael, et al.
Publicado: (2013)

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
por: Bergmann, P, et al.
Publicado: (2009)

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
por: Body, J.-J., et al.
Publicado: (2012)

Loading and Skeletal Development and Maintenance
por: Bergmann, P., et al.
Publicado: (2010)

Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Bruyère, Olivier, et al.
Publicado: (2017)

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture
por: Ferrari, Serge, et al.
Publicado: (2016)

Publication outcomes of the abstracts presented at the 2011 European Congress on Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ECCEO-IOF11): A position paper of the European Society for Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculo-Skeletal Diseases (ESCEO) and the International Osteoporosis and Other Skeletal Diseases Foundation (IOF)
por: Rabenda, Véronique, et al.
Publicado: (2015)

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
por: Reginster, J-Y., et al.
Publicado: (2011)

Vitamin D inadequacy in Belgian postmenopausal osteoporotic women
por: Neuprez, Audrey, et al.
Publicado: (2007)

Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO)
por: Cianferotti, Luisella, et al.
Publicado: (2017)

Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
por: Bruyère, Olivier, et al.
Publicado: (2008)

Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis
por: Beaudart, Charlotte, et al.
Publicado: (2023)

Adverse Reactions and Drug–Drug Interactions in the Management of Women with Postmenopausal Osteoporosis
por: Rizzoli, René, et al.
Publicado: (2011)

Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art—outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Diez-Perez, Adolfo, et al.
Publicado: (2019)

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis
por: Bruyère, Olivier, et al.
Publicado: (2015)

Osteoporosis and sarcopenia: two diseases or one?
por: Reginster, Jean-Yves, et al.
Publicado: (2016)

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group
por: Chevalley, Thierry, et al.
Publicado: (2022)

Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs
por: Fuggle, N. R., et al.
Publicado: (2020)

Intervention thresholds and diagnostic thresholds in the management of osteoporosis
por: Kanis, John A., et al.
Publicado: (2022)

Experts’ preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS)
por: Beaudart, Charlotte, et al.
Publicado: (2021)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

Sarcopenia: burden and challenges for public health
por: Beaudart, Charlotte, et al.
Publicado: (2014)

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2023)

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF)
por: Hiligsmann, M., et al.
Publicado: (2019)

Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis
por: Lorentzon, Mattias, et al.
Publicado: (2019)

Recommendations for the Reporting of Harms in Manuscripts on Clinical Trials Assessing Osteoarthritis Drugs: A Consensus Statement from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Honvo, Germain, et al.
Publicado: (2019)

Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
por: Pavelka, Karel, et al.
Publicado: (2016)

Patients’ preferences for osteoporosis drug treatment: a discrete-choice experiment
por: Hiligsmann, Mickaël, et al.
Publicado: (2014)

Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging
por: Ladang, Aurélie, et al.
Publicado: (2023)

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis
por: Honvo, Germain, et al.
Publicado: (2019)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Correction: Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the Centre Académique de Recherche et d'Expérimentation en Santé (CARES SPRL), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging
por: Ladang, Aurélie, et al.
Publicado: (2023)

The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation
por: Cianferotti, Luisella, et al.
Publicado: (2017)

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty
por: Arden, Nigel, et al.
Publicado: (2015)

Measures of attributes of locomotor capacity in older people: a systematic literature review following the COSMIN methodology
por: Honvo, Germain, et al.
Publicado: (2023)

Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
por: Moon, Rebecca J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8j60blrlmn6q4cb2i89jhr2s4j